TP53 and neoplasm: However, despite numerous therapeutic options, tumor detection in an advanced stage, the existence of other concomitant diseases, and the presence of mutations in tumor cells, such as p53 mutations, favor tumor development and therapeutic resistance (Chen et al., 2003; Kunst et al., 2016; Caron de Fromentel and Levrero, 2020).